WeVote
Log In

Bill

Bill

HF 3444

Use of prior authorization and step therapy for drugs used in the treatment of opioid use disorder under medical assistance prohibited.

2025-2026 Regular Session Introduced by Dave Baker and 3 co-sponsors

HF 3444 bans prior authorization and step therapy for opioid use disorder meds under Minnesota MA, enabling faster, barrier-free access to treatment.

Authors added Baker, Noor
#drugsandmedicine #humanservicesandhumanservicesdepartment
0
WeVote Research Nonpartisan
Bill Summary · HF 3444

Summary of HF 3444 (Minnesota, 2025-2026)

Purpose and Intent

HF 3444 prohibits the use of prior authorization and step therapy requirements for drugs used in the treatment of opioid use disorder (OUD) under Minnesota Medical Assistance (MA, Minnesota’s Medicaid program). The bill aims to remove administrative barriers that can delay or restrict access to evidence-based medications for OUD, ensuring timely and appropriate treatment for individuals enrolled in MA.

Key Provisions

  • Prohibition on prior authorization (PA): MA cannot require prior authorization for medications approved for the treatment of opioid use disorder. This includes drugs commonly used in medication-assisted treatment (MAT), such as buprenorphine, methadone (where applicable under MA), and other approved OUD therapies.

  • Prohibition on step therapy (utilization management): MA cannot enforce step therapy protocols for OUD medications. Step therapy would be prevented from delaying access to first-line, clinically appropriate treatments for OUD.

  • Scope of medications: The prohibition applies to drugs used in the treatment of opioid use disorder that are covered by MA. The bill does not specify all eligible drugs in the text provided, but it targets those used for MAT and related OUD therapies.

  • Administration and enforcement: The bill sets expectations that MA administers OUD treatments without requiring PA or step therapy, aligning administrative practices with evidence-based treatment guidelines.

Who Would Be Affected

  • Minnesota Medical Assistance enrollees with OUD: Individuals seeking treatment for opioid use disorder would benefit from faster, barrier-free access to medically appropriate medications.

  • Prescribers and treating providers: Clinicians who provide MAT would face fewer administrative hurdles when initiating or continuing treatment with MA beneficiaries.

  • Managed care organizations and MA program administrators: Entities responsible for administering MA would need to adjust policies and workflows to remove PA and step therapy requirements for OUD medications.

Procedural and Timeline Aspects

  • Introduction and referral:
    • Introduced and first read on February 19, 2026; referred to Health Finance and Policy.
  • Author and sponsor additions:
    • As of February 23, 2026, additional authors/sponsors added: Baker, Noor, Mahamoud, Bierman, and others, indicating cross-chamber support and coalition-building.
  • Next steps (typical):
    • Bill would advance through committee hearings in Health Finance and Policy, potential amendments, and then floor votes in the Minnesota House if it progresses, with eventual consideration by the Senate and Governor for enactment.

Potential Impact

  • Clinical impact: Reduced delays in initiating or continuing MAT for OUD, potentially improving retention in treatment and outcomes for individuals with opioid dependence.
  • System impact: Simplification of MA coverage processes for OUD medications, reducing administrative burden on prescribers and patients.
  • Policy alignment: The bill aligns MA policies with best-practice guidelines that emphasize rapid access to treatment for substance use disorders.

If you’d like, I can compare HF 3444 to existing Minnesota MA policies or provide a brief impact assessment from stakeholder perspectives (patients, providers, payers).

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.